Pharmacological prevention of atrial tachycardia induced atrial remodeling as a potential therapeutic strategy

PACE - Pacing and Clinical Electrophysiology

Volumn 26, Issue 3, 2003, Pages 752-764

  Shinagawa, Kaori ^a   Derakhchan, Katayoun ^a   Nattel, Stanley ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Antiarrhythmic drugs; Calcium channel blockers; Heart rhythm disorders; Ion channels; L type Ca2+ channels; T type Ca2+ channels

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIOXIDANT; ASCORBIC ACID; ATROPINE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; CANDESARTAN; CAPTOPRIL; CARIPORIDE; CONNEXIN 40; CONNEXIN 43; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FLECAINIDE; GLIBENCLAMIDE; ITRACONAZOLE; MIBEFRADIL; POTASSIUM CHANNEL BLOCKING AGENT; PROCAINAMIDE; PROPAFENONE; PROPRANOLOL; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; VERAPAMIL;

AUTONOMIC NERVOUS SYSTEM; CARDIOVERSION; DOG; DRUG EFFICACY; DRUG POTENTIATION; GOAT; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART DEPOLARIZATION; HEART MUSCLE POTENTIAL; NONHUMAN; OXIDATION; REFRACTORY PERIOD; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SINUS NODE CONDUCTION VELOCITY; SUPRAVENTRICULAR PREMATURE BEAT; SUPRAVENTRICULAR TACHYCARDIA;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTIOXIDANTS; ATRIAL FIBRILLATION; CALCIUM CHANNEL BLOCKERS; ELECTROPHYSIOLOGY; HEART ATRIA; HEART CONDUCTION SYSTEM; HUMANS; POTASSIUM CHANNEL BLOCKERS; SODIUM CHANNEL BLOCKERS; TACHYCARDIA; TIME FACTORS;

EID: 0037357223     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9592.2003.00128.x     Document Type: Review

References (95)

1. Wijffels MC, Kirchhof CJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats. Circulation 1995; 92:1954-1968.
2. Morillo CA, Klein GJ, Jones DL, et al. Chronic rapid atrial pacing. Structural, functional, and EP characteristics of a new model of sustained atrial fibrillation. Circulation 1995; 91:1588-1595.
3. Gaspo R, Bosch RF, Talajic M, et al. Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model. Circulation 1997; 96:4027-4035.
4. Nattel S, Li D. Ionic remodeling in the heart: Pathophysiological significance and new therapeutic opportunities for atrial fibrillation. Circ Res 2000; 87:440-447.
5. Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation: A population-based study over three decades. N Engl J Med 1987; 317:669-674.
6. Gaspo R, Bosch RF, Talajic M, et al. Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model. Circulation 1997; 96:4027-4035.
7. Elvan A, Wylie K, Zipes DP. Pacing-induced chronic atrial fibrillation impairs sinus node function in dogs. Electrophysiological remodeling. Circulation 1996; 94:2953-2960.
8. Fareh S, Villemaire C, Nattel S. Importance of refractoriness heterogeneity in the enhanced vulnerability to atrial fibrillation induction caused by tachycardia-induced atrial electrical remodeling. Circulation 1998; 98:2202-2209.
9. Nattel S: New ideas about atrial fibrillation 50 years on. Nature 2002; 415:219-226.
10. Yue L, Feng J, Gaspo R, et al. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997; 81:512-525.
11. Gaspo R, Bosch RF, Bou-Abboud E, et al. Tachycardia-induced changes in sodium current in a chronic dog model of atrial fibrillation. Circ Res 1997; 81:1045-1052.
12. Bosch RF, Zeng X, Grammer JB, et al. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res 1999; 44:121-131.
13. 2+ currents and human atrial fibrillation. Circ Res 1999; 85:428-436.
14. + current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation. Circ Res 1997; 80:772-781.
15. K,ACh and muscarinic receptor-mediated shortening of action potentials. Circulation 2001; 104:2551-2557.
16. Yue L, Melnyk P, Gaspo R, et al. Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. Circ Res 1999; 84:776-784.
17. Grammar JB, Bosch RF, Kuhlkamp V, et al. Molecular remodeling of Kv4.3 potassium channels in human atrial fibrillation. J Cardiovasc Electrophysiol 2000; 11:626-633.
18. Van Gelder IC, Brundel BJ, Henning RH, et al. Alterations in gene expression of proteins involved in the calcium handling in patients with atrial fibrillation. J Cardiovasc Electrophysiol 1999; 10:552-560.
19. Brundel BJ, van Gelder IC, Henning RH, et al. Gene expression of proteins influencing the calcium homeostasis in patients with persistent and paroxysmal atrial fibrillation. Cardiovasc Res 1999; 42:443-454.
20. 2+-ATPase mRNA in human atrial fibrillation without significant change in the mRNA of ryanodine receptor, calsequestrin and phospholamban: An insight into the mechanism of atrial electrical remodeling. J Am Coll Cardiol 1999; 33:1231-1237.
21. 2+ channel in persistent atrial fibrillation in humans. Z Kardiol 2000; 89(Suppl. 4):IV23-IV29.
22. Gaspo R, Sun H, Fareh S, et al. Dihydropyridine and beta adrenergic receptor binding in dogs with tachycardia-induced atrial fibrillation. Cardiovasc Res 1999; 42:434-442.
23. Brundel BJ, Van Gelder IC, Henning RH, et al. Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation. Circulation 2001; 103;684-690.
24. Goette A, Honeycutt C, Langberg JJ. Electrical remodeling in atrial fibrillation. Time course and mechanisms. Circulation 1996; 94:2968-2974.
25. Wijffels MC, Kirchhof CJ, Dorland R, et al. Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats: Role of neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation. Circulation 1997; 96:3710-3720.
26. Nattel S. Atrial electrophysiological remodeling caused by rapid atrial activation: Underlying mechanisms and clinical relevance to atrial fibrillation. Cardiovasc Res 1999; 42:298-308.
27. Sun H, Gaspo R, Leblanc N, et al. The cellular mechanisms of atrial contractile dysfunction caused by sustained atrial tachycardia. Circulation 1998; 98:719-727.
28. Hara M, Shvilkin A, Rosen MR, et al. Steady-state and nonsteady-state action potentials in fibrillating canine atrium: Abnormal rate adaptation and its possible mechanisms. Cardiovasc Res 1999; 42:455-469.
29. 2+-handling abnormalities. (abstract) Circulation 2000; 102(Suppl. II):II-192.
30. Jayachandran JV, Sih HJ, Winkle W, et al. Atrial fibrillation produced by prolonged rapid atrial pacing is associated with heterogeneous changes in atrial sympathetic innervation. Circulation 2000; 101:1185-1191.
31. Chang CM, Wu TJ, Zhou S, et al. Nerve sprouting and sympathetic hyperinnervation in a canine model of atrial fibrillation produced by prolonged right atrial pacing. Circulation 2001; 103:22-25.
32. Olgin J, Sih H, Hanish S, et al. Heterogeneous atrial denervation creates substrate for sustained atrial fibrillation. Circulation 1998; 98:2608-2614.
33. Elvan A, Huang XD, Pressler ML, et al. Radiofrequency catheter ablation of the atria eliminates pacing-induced sustained atrial fibrillation and reduces connexin43 in dogs. Circulation 1997; 96:1675-1685.
34. van der Velden HM, van Kempen MJ, Wijffels MC, et al. Altered pattern of connexin40 distribution in persistent atrial fibrillation in the goat. J Cardiovasc Electrophysiol 1998; 9:596-607.
35. van der Velden HMW, Ausma J, Rook MB, et al. Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat. Cardiovasc Res 2000; 46:476-486.
36. Kostin S, Klein G, Szalay Z, et al. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 2002; 54:361-379.
37. Polontchouk L, Haefliger JA, Ebelt B, et al. Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria. J Am Coll Cardiol 2001; 38:883-891.
38. Dupont E, Ko YS, Rothery S, et al. The gap-junctional protein connexin40 is elevated in patients susceptible to postoperative atrial fibrillation. Circulation 2001; 103:842-849.
39. Kanagaratnam P, Rothery S, Patel P, et al. Relative expression of immunolocalized connexins 40 and 43 correlates with human atrial conduction properties. J Am Coll Cardiol 2002; 39:116-123.
40. Sanfilippo AJ, Abascal VM, Sheehan M. Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. Circulation 1990; 82:792-797.
41. Suarez GS, Lampert S, Ravid S. Changes in left atrial size in patients with lone atrial fibrillation. Clin Cardiol 1991; 14:652-656.
42. Shi Y, Ducharme A, Li D, et al. Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation. Cardiovasc Res 2001; 52:217-225.
43. Ausma J, Wijffels M, Thone F, et al. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 1997; 96:3157-3163.
44. Courtemanche M, Ramirez RJ, Nattel S. Ionic mechanisms underlying human atrial action potential properties: Insights from a mathematical model. Am J Physiol 1998; 275:H301-H321.
45. Ramirez RJ, Nattel S, Courtemanche M. Mathematical analysis of canine atrial action potentials: Rate, regional factors and electrical remodeling. Am J Physiol (Heart Circ Physiol) 2000; 279:H1767-H1782.
46. Daoud EG, Knight BP, Weiss R, et al. Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Circulation 1997; 96:1542-1550.
47. Yu WC, Chen SA, Lee SH, et al. Tachycardia-induced change of atrial refractory period in humans: Rate dependency and effects of antiarrhythmic drugs. Circulation 1998; 97:2331-2337.
48. Leistad E, Aksnes G, Verburg E, et al. Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY K8644. Circulation 1996; 93:1747-1754.
49. Boyett MR, Jewell BR. Analysis of the effects of changes in rate and rhythm upon electrical activity in the heart. Prog Biophys Mol Biol 1980; 36:1-52.
50. Tieleman RG, De Langen CDJ, Van Gelder IC, et al. Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation 1997; 95: 1945-1953.
51. Lee SH, Yu WC, Cheng JJ, et al. Effect of verapamil on long-term tachycardia-induced atrial electrical remodeling. Circulation 2000; 101:200-206.
52. Fareh S, Benardeau A, Nattel S. Differential efficacy of L- and T-type calcium channel blockers in preventing tachycardia-induced atrial remodeling in dogs. Cardiovasc Res 2001; 49:762-770.
53. Bénardeau A, Fareh S, Nattel S. Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs. Cardiovasc Res 2001; 50:85-96.
54. Tieleman RG, Van Gelder IC, Crijns HJGM, et al. Early recurrences of atrial fibrillation after electrical cardioversion: A result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol 1998; 31:167-173.
55. De Simone A, Stabile G, Vitale DF, et al. Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. J Am Coll Cardiol 1999; 34:810-814.
56. Daoud EG, Hummel JD, Augostini R, et al. Effect of verapamil on immediate recurrence of atrial fibrillation. J Cardiovasc Electrophysiol 2000; 11:1231-1237.
57. Van Noord T, Van Gelder IC, Tieleman RG, et al. VERDICT: The Verapamil versus Digoxin Cardioversion Trial: A randomized study on the role of calcium lowering for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. J Cardiovasc Electrophysiol 2001; 12:766-769.
58. Bertaglia E, D'este D, Zanocco A, et al. Effects of pretreatment with verapamil on early recurrences after electrical cardioversion of persistent atrial fibrillation: A randomised study. Heart 2001; 85:578-580.
59. Villani GQ, Piepoli MF, Terracciano C, et al. Effects of diltiazem pretreatment on direct-current cardioversion in patients with persistent atrial fibrillation: A single-blind, randomized, controlled study. Am Heart J 2000; 140:437-443.
60. Tse HF, Wang Q, Yu CM, et al. Effect of verapamil on prevention of atrial fibrillation in patients implanted with an implantable atrial defibrillator. Clin Cardiol 2001; 24:503-505.
61. Sticherling C, Hsu W, Tada H, et al. Effects of verapamil and ibutilide on atrial fibrillation and postfibrillation atrial refractoriness. J Cardiovasc Electrophysiol 2002; 13:151-157.
62. Rosen MR, Danilo P Jr. Effects of tetrodotoxin, lidocaine, verapamil, and AHR-2666 on Ouabain- induced delayed afterdepolarizations in canine Purkinje fibers. Circ Res 1980; 46:117-124.
63. 2+ channels and pharmacological blockade: Potential pathophysiological relevance. Cardiovasc Drugs Ther 1997; 11:723-739.
64. 2+ channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling in dogs. Circulation 1999; 100:2191-2197.
65. 2+ current at physiologic temperatures relevant to the action potential in human atrial myocytes. Am J Physiol 1997; 272:H227-H235.
66. + channels involved in long QT syndromes, are targets for calcium channel blockers. Mol Pharmacol 1998; 54:695-703.
67. Eller P, Berjukov S, Wanner S, et al. High affinity interaction of mibefradil with voltage-gated calcium and sodium channels. Br J Pharmacol 2000; 130:669-677.
68. Welker HA, Wiltshire H, Bullingham R. Clinical pharmacokinetics of mibefradil. Clin Pharmacokinet 1998; 35:405-423.
69. Larosa E, Cauwenbergh G, Cilli P, et al. Itraconazole pharmacokinetics in the female genital tract: Plasma and tissue levels in patients undergoing hysterectomy after a single dose of 200 mg itraconazole. Eur J Obstet Gynecol Reprod Biol 1986; 23:85-89.
70. Jayachandran JV, Winkle W, Sih HJ, et al. Chronic atrial fibrillation from rapid atrial pacing is associated with reduced atrial blood flow: A positron emission tomography study. (abstract) Circulation 1998; 98:I-209.
71. Ausma J, Wijffels M, Thone F, et al. Structural changes of atrial myocardium due to sustained atrial fibrillation in goat. Circulation 1997; 96:3157-3163.
72. Karmazyn M, Gan XT, Humphreys RA, et al. The myocardial Na(+)-H(+) exchange: Structure, regulation, and its role in heart disease. Circ Res 1999; 85:777-786.
73. + exchange during ischemia and reperfurion of normal and diabetic rat hearts. Cardiovasc Res 1990; 24:873-878.
74. + antiporter inhibitor on postischemic reperfusion in pig heart. J Cardiovasc Pharmacol 1994; 23:72-78.
75. + exchange inhibitor and its effects in cardiac ischemia. Br J Pharmacol 1993; 109:562-568.
76. Anderson SE, Murphy E, Steenbergen C, et al. Na-H exchange in myocardium: Effects of hypoxia and acidification on Na and Ca. Am J Physiol 1990; 259:C940-C948.
77. Murphy E, Perlman M, London RE, et al. Amiloride delays the ischemia-induced rise in cytosolic free calcium. Circ Res 1991; 68:1250-1258.
78. +) exchange inhibition reduces hypertrophy and heart failure after myocardial infarction in rats. Am J Physiol (Heart Circ Physiol) 2001; 280:H738-H745.
79. Gazmuri RJ, Ayoub IM, Hoffner E, et al. Successful ventricular defibrillation by the selective sodium-hydrogen exchanger isoform-1 inhibitor cariporide. Circulation 2001; 104:234-239.
80. + exchanger in short-term atrial electrophysiological remodeling. Circulation 2000; 101:1861-1866.
81. + exchanger delays the development of rapid pacing-induced atrial contractile dysfunction. Circulation 2001; 103:762-768.
82. +-exchange or angiotensin converting enzyme on atrial tachycardia-induced remodeling. Cardiovasc Res 2002; 54:438-446.
83. Ausma J, Coumans WA, Duimel H, et al. Atrial high energy phosphate content and mitochondrial enzyme activity during chronic atrial fibrillation. Cardiovasc Res 2000; 47:788-796.
84. Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100:376-380.
85. Goette A, Staack T, Rocken C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000; 35:1669-1677.
86. Goette A, Arndt M, Rocken C, et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000; 101:2678-2781.
87. Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101:2612-2617.
88. Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001; 104:2608-2614.
89. Tieleman RG, Blaauw Y, Gelder IC, et al. Flecainide reduces tachycardia-induced electrical remodeling of the atria. (abstract) Circulation 1998; 98:I-695.
90. Shinagawa K, Shiroshita-Takeshita A, Schram G, et al. Is amiodarone's unique efficacy in AF due to inhibition of atrial tachycardia remodeling? (abstract) Circulation (in press).
91. Miyata A, Zipes DP, Hall S, et al. Kb-R7943 prevents acute, atrial fibrillation-induced shortening of atrial refractoriness in anesthetized dogs. Circulation 2002; 106:1410-1419.
92. Mihm MJ, Yu F, Carnes CA, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001; 104:174-180.
93. Carnes CA, Chung MK, Nakayama T, et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 2001; 89:e32-e38.
94. Mason RP, Mak IT, Walter MF, et al. Antioxidant and cytoprotective activities of the calcium channel blocker mibedradil. Biochem Pharmacol 1998; 55:1843-1852.
95. Sun H, Chartier D, Leblanc N, et al. Intracellular calcium changes and tachycardia-induced contractile dysfunction in canine atrial myocytes. Cardiovasc Res 2001; 49:751-761.